Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Pierian Biosciences develops and validates proprietary diagnostic assays—ChemoINTEL™, ImmunoINTEL™, and PathwayINTEL™—to provide actionable information guiding personalized treatment decisions in oncology. Their lead clinical study uses these assays to predict tumor sensitivity to chemotherapy in advanced epithelial ovarian cancer patients. Collaborations with major academic centers such as Clatterbridge Cancer Centre support their translational research efforts. No therapeutics developed; no FDA-approved commercial products yet reported.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Pierian Biosciences.